{"id":313491,"date":"2026-10-16T13:06:59","date_gmt":"2026-10-16T07:36:59","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=313491"},"modified":"2026-10-16T13:06:59","modified_gmt":"2026-10-16T07:36:59","slug":"auropharma-best-stock-in-its-sector-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/","title":{"rendered":"Is Aurobindo Pharma the Best Stock in Its Sector? A Look at the Numbers"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Aurobindo Pharma CMP Rs 1,678 (16 Oct 2026). Market cap Rs 96,376 Cr. ROE 9.25%. P\/E 25.97x versus Industry P\/E 36.42x.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Aurobindo Pharma is one of the names investors compare when screening the Pharmaceuticals sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.<\/p>\n<\/p><\/div>\n<p>Is <a href=\"https:\/\/univest.in\/stocks\/auropharma\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma<\/a> the best stock in its sector? The stock trades on the NSE at Rs 1,678 as of 16 October 2026, within its 52-week range of Rs 1,080.10 to Rs 1,740.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/abbott-india-best-stock-in-its-sector\">Is Abbott India the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=auropharma-best-stock-in-its-sector\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#About_Aurobindo_Pharma\" title=\"About Aurobindo Pharma\">About Aurobindo Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#Is_Aurobindo_Pharma_the_Best_Stock_in_Its_Sector\" title=\"Is Aurobindo Pharma the Best Stock in Its Sector?\">Is Aurobindo Pharma the Best Stock in Its Sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#How_Aurobindo_Pharma_Compares_Against_Its_Pharmaceuticals_Sector_Peers\" title=\"How Aurobindo Pharma Compares Against Its Pharmaceuticals Sector Peers\">How Aurobindo Pharma Compares Against Its Pharmaceuticals Sector Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#What_Makes_Aurobindo_Pharma_Worth_Watching_in_Pharmaceuticals\" title=\"What Makes Aurobindo Pharma Worth Watching in Pharmaceuticals\">What Makes Aurobindo Pharma Worth Watching in Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#Aurobindo_Pharma_Valuation_Is_It_Justified\" title=\"Aurobindo Pharma Valuation: Is It Justified?\">Aurobindo Pharma Valuation: Is It Justified?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#How_to_Track_Aurobindo_Pharma_Before_You_Invest\" title=\"How to Track Aurobindo Pharma Before You Invest\">How to Track Aurobindo Pharma Before You Invest<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#Is_Aurobindo_Pharma_the_best_stock_in_its_sector\" title=\"Is Aurobindo Pharma the best stock in its sector?\">Is Aurobindo Pharma the best stock in its sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#What_is_the_current_share_price_of_Aurobindo_Pharma\" title=\"What is the current share price of Aurobindo Pharma?\">What is the current share price of Aurobindo Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#What_sector_does_Aurobindo_Pharma_belong_to\" title=\"What sector does Aurobindo Pharma belong to?\">What sector does Aurobindo Pharma belong to?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#How_does_Aurobindo_Pharma_compare_to_its_sector_peers_on_PE\" title=\"How does Aurobindo Pharma compare to its sector peers on P\/E?\">How does Aurobindo Pharma compare to its sector peers on P\/E?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#What_is_Aurobindo_Pharmas_return_on_equity\" title=\"What is Aurobindo Pharma&#8217;s return on equity?\">What is Aurobindo Pharma&#8217;s return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/auropharma-best-stock-in-its-sector-2\/#Should_I_invest_in_Aurobindo_Pharma_based_on_its_sector_position\" title=\"Should I invest in Aurobindo Pharma based on its sector position?\">Should I invest in Aurobindo Pharma based on its sector position?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Aurobindo_Pharma\"><\/span><strong>About Aurobindo Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma Ltd is a Hyderabad based drug maker with a global footprint in generic medicines. Its business includes oral and injectable formulations, active pharmaceutical ingredients and a growing biosimilars effort, with the United States and Europe as major markets. At a market capitalisation of Rs 96,376 Cr, it is tracked as part of the Pharmaceuticals sector on Univest.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_Aurobindo_Pharma_the_Best_Stock_in_Its_Sector\"><\/span><strong>Is Aurobindo Pharma the Best Stock in Its Sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma makes its case as the best stock in its sector primarily on valuation relative to its Industry P\/E, backed by its return on equity. Aurobindo Pharma&#8217;s 25.97x P\/E is below the 36.42x Industry P\/E, though above Lupin at 16.14x and Zydus Lifesciences at 24.78x, while its 9.25% ROE is lower than Lupin at 23.76% and Zydus Lifesciences at 18.59%, and its debt to equity ratio of 0.21 is below Lupin at 0.29 and Zydus Lifesciences at 0.46.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Metric<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Aurobindo Pharma<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">CMP (NSE)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 1,677.90<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">52-Week High \/ Low<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 1,740.00 \/ Rs 1,080.10<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Market Cap<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 96,376 Cr<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">P\/E (TTM) vs Industry P\/E<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">25.97x vs 36.42x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">P\/B<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2.54<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">ROE<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">9.25%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">EPS (TTM)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 64.49<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Dividend Yield<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.24%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Debt to Equity<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.21<\/td>\n<\/tr>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Aurobindo Pharma Against Other Pharmaceuticals Sector Stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Aurobindo_Pharma_Compares_Against_Its_Pharmaceuticals_Sector_Peers\"><\/span><strong>How Aurobindo Pharma Compares Against Its Pharmaceuticals Sector Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets Aurobindo Pharma against 2 other Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P\/E, ROE and debt to equity, calculated across the 2 peer companies.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Debt to Equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/auropharma\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma<\/a><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">96,376<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">25.97<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">9.25%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.21<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Lupin<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">89,592<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">16.14<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">23.76%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.29<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1,13,790<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">24.78<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">18.59%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.46<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>Peer average (2 companies)<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">&#8211;<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>20.46<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>21.18%<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>0.38<\/strong><\/td>\n<\/tr>\n<\/table>\n<p>Measured against the peer averages, Aurobindo Pharma&#8217;s P\/E is 27 percent above the 20.46x average, and its ROE is 11.93 percentage points below the 21.18% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Makes_Aurobindo_Pharma_Worth_Watching_in_Pharmaceuticals\"><\/span><strong>What Makes Aurobindo Pharma Worth Watching in Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Scale:<\/strong> At Rs 96,376 Cr, its market capitalisation is larger than Lupin (Rs 89,592 Cr), though smaller than Zydus Lifesciences (Rs 1,13,790 Cr), which is a useful reminder that the peers differ in size as well as in valuation.<\/li>\n<li><strong>Sector drivers:<\/strong> Launches of new generics and injectables, steady demand in regulated markets and progress in biosimilars influence its growth.<\/li>\n<li><strong>Key risk:<\/strong> Price erosion in US generics and regulatory inspections at plants can weigh on margins, and its return on equity trails several large peers.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Valuation_Is_It_Justified\"><\/span><strong>Aurobindo Pharma Valuation: Is It Justified?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At a P\/B ratio of 2.54, the market pays about Rs 2.54 for every rupee of book value, and the EPS (TTM) of Rs 64.49 is the earnings base behind the P\/E. The stock trades about 4 percent below its 52-week high and about 55 percent above its 52-week low. The dividend yield of 0.24% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/ofss-best-stock-in-its-sector\">Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Aurobindo Pharma and other Pharmaceuticals sector stocks.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Track_Aurobindo_Pharma_Before_You_Invest\"><\/span><strong>How to Track Aurobindo Pharma Before You Invest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Before deciding whether Aurobindo Pharma deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceuticals sector peers using the steps below.<\/p>\n<ol>\n<li>Open the Univest Screener and search for Aurobindo Pharma to view live price, valuation ratios, and peer comparisons within the Pharmaceuticals sector.<\/li>\n<li>Compare its P\/E, P\/B, and ROE against other Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.<\/li>\n<li>Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.<\/li>\n<li>Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.<\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Pharmaceuticals depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Is_Aurobindo_Pharma_the_best_stock_in_its_sector\"><\/span><strong>Is Aurobindo Pharma the best stock in its sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Aurobindo Pharma has a 9.25% ROE and trades at 25.97x P\/E against a 36.42x Industry P\/E. Against the 2 peers compared in this article, its ROE is below the 21.18% peer average and its P\/E is above the 20.46x peer average. Its debt to equity ratio of 0.21 is below the 0.38 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_current_share_price_of_Aurobindo_Pharma\"><\/span><strong>What is the current share price of Aurobindo Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma was trading at Rs 1,677.90 on the NSE as of 16 October 2026, and its 52-week range runs from Rs 1,080.10 to Rs 1,740.00. That leaves the share price 4 percent short of the 52-week high and 55 percent clear of the 52-week low. Its market capitalisation is Rs 96,376 Cr and its EPS (TTM) is Rs 64.49, which is the earnings figure behind the 25.97x P\/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Aurobindo_Pharma_belong_to\"><\/span><strong>What sector does Aurobindo Pharma belong to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.42x Industry P\/E used in this article. The 2 named peers compared here are Lupin and Zydus Lifesciences, chosen as comparable listed names so that the P\/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Aurobindo_Pharma_compare_to_its_sector_peers_on_PE\"><\/span><strong>How does Aurobindo Pharma compare to its sector peers on P\/E?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma&#8217;s P\/E of 25.97x is above the 20.46x average of the 2 named peers, with Lupin at 16.14x and Zydus Lifesciences at 24.78x. It also sits below the 36.42x Industry P\/E, which is the benchmark for the wider Pharmaceuticals sector. A P\/E that is above a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P\/B ratio of 2.54 gives one more view of how the market values its book value.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Aurobindo_Pharmas_return_on_equity\"><\/span><strong>What is Aurobindo Pharma&#8217;s return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma reported a return on equity of 9.25%, which is below the 21.18% average of its named peers, with Lupin at 23.76% and Zydus Lifesciences at 18.59%. ROE shows how much profit a company generates on every rupee of shareholders&#8217; equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.21 against a peer average of 0.38. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_invest_in_Aurobindo_Pharma_based_on_its_sector_position\"><\/span><strong>Should I invest in Aurobindo Pharma based on its sector position?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sector position is only one input into an investment decision. Aurobindo Pharma has a 9.25% ROE and a 25.97x P\/E, which make it worth researching further, and its dividend yield is 0.24%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Is Aurobindo Pharma the best stock in its sector?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Aurobindo Pharma has a 9.25% ROE and trades at 25.97x P\/E against a 36.42x Industry P\/E. Against the 2 peers compared in this article, its ROE is below the 21.18% peer average and its P\/E is above the 20.46x peer average. Its debt to equity ratio of 0.21 is below the 0.38 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.\"}},{\"@type\":\"Question\",\"name\":\"What is the current share price of Aurobindo Pharma?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma was trading at Rs 1,677.90 on the NSE as of 16 October 2026, and its 52-week range runs from Rs 1,080.10 to Rs 1,740.00. That leaves the share price 4 percent short of the 52-week high and 55 percent clear of the 52-week low. Its market capitalisation is Rs 96,376 Cr and its EPS (TTM) is Rs 64.49, which is the earnings figure behind the 25.97x P\/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.\"}},{\"@type\":\"Question\",\"name\":\"What sector does Aurobindo Pharma belong to?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.42x Industry P\/E used in this article. The 2 named peers compared here are Lupin and Zydus Lifesciences, chosen as comparable listed names so that the P\/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.\"}},{\"@type\":\"Question\",\"name\":\"How does Aurobindo Pharma compare to its sector peers on P\/E?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma's P\/E of 25.97x is above the 20.46x average of the 2 named peers, with Lupin at 16.14x and Zydus Lifesciences at 24.78x. It also sits below the 36.42x Industry P\/E, which is the benchmark for the wider Pharmaceuticals sector. A P\/E that is above a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P\/B ratio of 2.54 gives one more view of how the market values its book value.\"}},{\"@type\":\"Question\",\"name\":\"What is Aurobindo Pharma's return on equity?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Aurobindo Pharma reported a return on equity of 9.25%, which is below the 21.18% average of its named peers, with Lupin at 23.76% and Zydus Lifesciences at 18.59%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.21 against a peer average of 0.38. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.\"}},{\"@type\":\"Question\",\"name\":\"Should I invest in Aurobindo Pharma based on its sector position?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sector position is only one input into an investment decision. Aurobindo Pharma has a 9.25% ROE and a 25.97x P\/E, which make it worth researching further, and its dividend yield is 0.24%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Is Aurobindo Pharma the best stock in its Pharmaceuticals sector? A data-driven comparison against named peers on P\/E, ROE and more.<\/p>\n","protected":false},"author":29,"featured_media":313490,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[5839,1019],"class_list":["post-313491","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-sector-stocks","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["313490"],"rank_math_title":["Is Aurobindo Pharma the Best Stock in Its Sector? A Look at the Numbers"],"rank_math_description":["Is Aurobindo Pharma the best stock in its Pharmaceuticals sector? A data-driven comparison against named peers on P\/E, ROE and more."],"rank_math_focus_keyword":["Is Aurobindo Pharma the Best Stock in Its Sector? A Look at the Numbers"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/is-aurobindo-pharma-the-best-stock-in-its-sector-a-look-at-the-numbers-1.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/313491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=313491"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/313491\/revisions"}],"predecessor-version":[{"id":313492,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/313491\/revisions\/313492"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/313490"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=313491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=313491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=313491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}